Effect of Thyrotropin Level on Iodine Uptake in Metastatic Differentiated Thyroid Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-06

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Distant metastases is the leading cause of differentiated thyroid cancer-related death. Radioactive iodine (RAI) treatment is the most effective therapy for RAI-avid metastatic differentiated thyroid cancer (DTC). It is well known that the efficacy of RAI therapy is depend on the sodium-iodide symporter protein, which can be synthesized by elevated thyrotropin stimulation. Therefore, thyrotropin stimulation before RAI treatment to ensure sufficient uptake of RAI has been a long-established procedure. According to some observational studies, thyrotropin of 25-30 μIU/mL has been adopted as the standard care protocol. However, whether thyrotropin of 25-30 μIU/mL is enough to stimulate iodine uptake in metastatic lesions remains unknown. In this study, the investigators aim to address the effect of thyrotropin on iodine uptake in metastatic DTC during levothyroxine withdrawal by two times 124I PET/CT scans on different endogenous thyrotropin levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Differentiated Thyroid Cancer Patients Treated With Different Doses of Radioactive Iodine.

NCT06134830

Thyroid Cancer

NOT_YET_RECRUITING

Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry

NCT05299437

Metastatic Differentiated Thyroid Cancer

UNKNOWN PHASE2

Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases

NCT00749697

Thyroid Carcinoma Metastatic Sites Lung Bone Nodal

UNKNOWN NA

Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma

NCT03647358

Thyroid Carcinoma Metastatic Thyroid Carcinoma

RECRUITING PHASE1

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

NCT06443866

Thyroid Cancer RAI-Refractory Thyroid Cancer

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

It is estimated that 10 patients who met the study criteria will be enrolled. All patients underwent twice 124I PET/CT scans in Beijing Cancer Hospital. The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Differentiated Thyroid Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

124I PET/CT

All eligible patients will be allocated to this arm (single-arm study).

Group Type EXPERIMENTAL

124I PET/CT

Intervention Type DIAGNOSTIC_TEST

The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

124I PET/CT

The first 124I PET/CT was prepared with endogenous thyrotropin 30±10 μIU/mL, and the second 124I PET/CT was prepared with endogenous thyrotropin \>100 μIU/mL. The RAI-avidity of the metastases was assessed twice along with the levothyroxine withdrawal by 124I PET/CT scans.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients underwent total thyroidectomy.
2. Patients were diagnosed with differentiated thyroid cancer by postoperative pathological examination.
3. Distant metastases confirmed by CT etc.